Hetero Introduces HumiraTM Biosimilar in Indian Market
India’s leading generic pharmaceutical company and the world’s largest producer of anti-retroviral drugs, Hetero, has now announced the launch of its fourth biosimilar drug ‘Adalimumab’ under the brand name ‘MaburaTM’ in India.
This new medicine is a a biosimilar version of AbbVie’s Humira. This medicine will be marketed and distributed in India by Hetero Healthcare company. This will be made at the company’s Hyderabad facility.
MaburaTM will be available as a pre-filled syringe (PFS) of 40mg and is administered subcutaneously. AbbVie’s HumiraTM. Adalimumab, is the first fully human monoclonal antibody which was first approved by US FDA in 2002.
This is a TNF-inhibiting and anti-inflammatory medication. This works in a way, it binds to tumor necrosis factor-alpha (TNFα) and reduces inflammatory response. Treatment with adalimumab may increase the chance of infections as body’d natural immunity is suppressed.
The drug is indicated for the treatment of various conditions like Crohn’s disease, ulcerative colitis, chronic psoriasis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurative and juvenile idiopathic arthritis.
